Macrolide antibacterial agent fidaxomicin may be an alternative to vancomycin for Clostridium difficile-associated diarrhea

Fidaxomicin, a macrolide antibiotic, is noninferior to vancomycin in the treatment of Clostridium difficile diarrhea in terms of clinical cure. This was the main finding of a recent randomized trial that sought to demonstrate the noninferiority of fidaxomicin for this indication.

C difficile, which causes 15% to 25% of antibiotic-associated diarrhea, has been increasing in frequency and severity in India in recent years due to the emergence of virulent strains [Indian J Med Microbiol. 2009;27(4):289-300].

In the recent study, 535 patients from Europe, Canada, and the United States were randomized for 10 days to receive either oral vancomycin 125 mg every 6 hours or...

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Gastroenterology, Infectious Disease, Pharmacology, Primary Care and tagged , , , , , , , , . Volume: .

Post a Comment

You must be logged in to post a comment.